Vertex regulatory update

VRTX received U.S. Patent No. 5,543,423 covering VX-853 and related compounds. VTRX is developing VX-853 to treat cancer multidrug resistance, which limits the efficacy of many chemotherapy regimens. In laboratory studies, VX-853 blocks both P-glycoprotein and MRP, two proteins central to broad resistance to anti-cancer drugs. ...